Passage BIO (PASG) Common Equity (2019 - 2026)
Passage BIO (PASG) posted quarterly Common Equity of $11.8 million for Q1 2026, down 74.84% year-over-year from $46.7 million in Q1 2025, and down 37.34% quarter-over-quarter from $18.8 million in Q4 2025.
Passage BIO (PASG) Common Equity (2019 - 2026) Analysis & Trends
Passage BIO's Common Equity history runs 8 years deep, the most recent figure standing at $11.8 million for Q1 2026.
- In Q1 2026, Common Equity fell 74.84% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 74.84% YoY), while the FY2025 annual figure was $18.8 million, down 69.39% from the prior year.
- Common Equity for Q1 2026 stood at $11.8 million, down from $18.8 million in the prior quarter.
- The five-year high for Common Equity was $281.3 million in Q1 2022, with the low at $11.8 million in Q1 2026.
- The 5-year median for Common Equity is $104.9 million (2024), against an average of $117.0 million.
- The sharpest annual moves came in 2022 and 2026: Common Equity sank 36.28% in 2022, then sank 74.84% in 2026.
- Passage BIO's Common Equity stood at $201.4 million in 2022, then plunged by 44.74% to $111.3 million in 2023, then plunged by 44.95% to $61.3 million in 2024, then tumbled by 69.39% to $18.8 million in 2025, then slumped by 37.34% to $11.8 million in 2026.
- Business Quant data shows PASG's Common Equity at $11.8 million in Q1 2026, $18.8 million in Q4 2025, and $31.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Passage BIO | 15.16 Mn | 15.16 Mn | - | 4.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.46 Mn |
| Mar 31, 2026 | 11.75 Mn |
| Dec 31, 2025 | 18.76 Mn |
| Sep 30, 2025 | 31.12 Mn |
| Jun 30, 2025 | 38.26 Mn |
| Mar 31, 2025 | 46.71 Mn |
| Dec 31, 2024 | 61.26 Mn |
| Sep 30, 2024 | 72.72 Mn |
| Jun 30, 2024 | 90.56 Mn |
| Mar 31, 2024 | 104.88 Mn |
| Dec 31, 2023 | 111.28 Mn |
| Sep 30, 2023 | 126.28 Mn |
| Jun 30, 2023 | 150.41 Mn |
| Mar 31, 2023 | 170.35 Mn |
| Dec 31, 2022 | 201.37 Mn |
| Sep 30, 2022 | 224.40 Mn |
| Jun 30, 2022 | 248.05 Mn |
| Mar 31, 2022 | 281.31 Mn |
| Dec 31, 2021 | 318.66 Mn |
| Sep 30, 2021 | 362.23 Mn |